From July 1, 2023 to September 30, 2023, the company has repurchased 149,041 shares, representing 0.48% for $0.17 million. With this, the company has completed the repurchase of 4,708,520 shares, representing 14.3% for $15.42 million under the buyback announced on March 15, 2022.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.275 USD | -4.14% | -13.79% | -6.02% |
14/06 | Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform | CI |
13/05 | HC Wainwright Adjusts Price Target on Co-Diagnostics to $2 From $2.50, Maintains Neutral Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.02% | 41.6M | |
-34.99% | 14.88B | |
-54.41% | 2.26B | |
+16.54% | 1.89B | |
-11.85% | 1.52B | |
+19.90% | 1.19B | |
-29.99% | 871M | |
+2.21% | 781M | |
-35.68% | 750M | |
-29.12% | 591M |
- Stock Market
- Equities
- CODX Stock
- News Co-Diagnostics, Inc.
- Tranche Update on Co-Diagnostics, Inc.'s Equity Buyback Plan announced on March 15, 2022.